Conference Reports for NATAP

Back

64rd Annual Meeting of the American Association for the Study of Liver Diseases Washington, DC Nov 1-5 2013     Summary from AASLD 2013 for Hepatitis C Washington 1-5 November 2013 - Written by Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany - (12/02/13)   New Phase II Data from All-Oral Regimens - written by Fred Poordad, MD VP, Academic and Clinical Affairs The Texas Liver Institute Professor of Medicine University of Texas Health Science Center San Antonio, Texas- (11/18/13)   Population Pharmacokinetics of Sofosbuvir and Its Major Metabolite (GS-331007) in Healthy and HCV-Infected Adult Subjects - (12/21/15)   Predicted Future HCV Liver Disease Burden - "Predicting Utilization of Liver Transplantation for Hepatitis C-related Liver Disease in the United States" - (05/29/15)   Comparison of the overall survival between patients with HCV-induced advanced hepatic fibrosis and the general population - (05/15/14)   Minimum costs to produce Hepatitis C Direct Acting Antivirals for access programs in developing countries - (12/20/13)   Anti-Fibrotic and Anti-Inflammatory Activity of the Dual CCR2 and CCR5 Antagonist Cenicriviroc in a Mouse Model of NASH - (12/11/13)   Telaprevir combination therapy in treatment-naïve and experienced patients co-infected with HCV and HIV - (12/06/13)   Using Laboratory Data to Predict Long-Term Morbidity and Mortality in Chronic Hepatitis C (& treatment affect) Patients in the U.S. Veterans Health Administration - (12/04/13)   2 Screening Studies - (12/04/13)   Safety Profile of Peginterferon Lambda for Treatment of Chronic Hepatitis B (CHB) or Chronic Hepatitis C (CHC): Cross-Study Analysis of Patients Treated in Three Phase 2 Studies - (12/04/13)   New HCV Protease Inhibitor:a phase 1/2a Study of Safety, Tolerability and Pharmacokinetic Profiles of TG-2349, a Pan-Genotypic HCV Protease Inhibitor, in Healthy East Asian and Caucasian Subjects, and its Antiviral Activity in Chronic Hepatitis C patients. - (12/04/13)   Twice Daily Telaprevir in Combination with Peginterferon Alfa-2a/Ribavirin in Genotype 1 HCV Liver Transplant Recipients: Interim Week 16 Calcineurin Inhibitor, Telaprevir, and Ribavirin Pharmacokinetics From the Prospective Multicenter REFRESH Study - (12/04/13)   Telaprevir in the Treatment of Acute HCV in HIV-infected Men - (12/04/13)   Efficacy, Treatment Duration and Safety of boceprevir/peginterferon/ribavirin in Treatment naive Patients With Hepatitis C Virus Genotype 1 Infection: relationship to baseline fibrosis score - (12/04/13)   Asunaprevir Pharmacokinetics and Safety in Subjects With Impaired Renal Function - (12/04/13)   Shifting scales: comparing viral hepatits and HIV/AIDS mortality in the Global Burden of Disease Study 2010 - (12/04/13)   New Monogram HCV Protease Inhibitor Resistance Test: "Cross-sectional Assessment of 1500 Clinical Samples Submitted for HCV NS3/4A Protease Inhibitor Drug Resistance Testing in the US" - (12/04/13)   High End-Of-Treatment (EOT) Response Rate with Telaprevir-PegIFN-RBV in Treatment-Experienced HIV Coinfected Patients with HCV genotype 1: ANRS HC26 TelapreVIH Study - (12/04/13)   W48 Response Rate of Boceprevir-PegIFN-RBV in Treatment-Experienced HIV Coinfected Patients with HCV genotype 1: ANRS-HC27 BocepreVIH Study - (12/04/13)   Daclatasvir Pharmacokinetics in Healthy Subjects: No Clinically Relevant Drug-Drug Interaction With Either Cyclosporine or Tacrolimus - (12/02/13)   Post-Treatment Viral Evolution Assessment Using Ultra-Deep Pyrosequencing in Samples from Patients with Hepatitis C Virus Infection: The EXTEND Study - (12/02/13)   Genome-wide Association Analysis to Evaluate Genetic Variations Associated with Rash Development in Telaprevir Phase 2 and 3 Studies - (12/02/13)   High Efficacy at Lower Doses of MK-5172 25 mg and 50 mg Daily for 12 Weeks in HCV Genotype (Gt)1 Treatment-Naive Noncirrhotic Patients - (12/02/13)   Vaniprevir (MK-7009) Demonstrates Higher Exposures in Treatment-Experienced Genotype (GT) 1 Cirrhotic Than Non-cirrhotic HCV-Infected Patients - (12/02/13)   Costs of Telaprevir-based Triple Therapy Including Adverse Event Management at the Mount Sinai Medical Center, NY $189,000 per SVR - (12/02/13)   Roche at AASLD - (11/26/13)   Entecavir Plus Tenofovir Combination Therapy in Patients with Multi-drug Resistant Chronic Hepatitis B - A multicenter, Prospective Study - Early Experience - (11/25/13)   Sustained Immune Control in HBeAg-Positive Chronic Hepatitis B Patients Who Switched From Long-Term Entecavir Therapy to Peginterferon Alfa-2a (40KD): 1-Year Follow-Up of the OSST Study - (11/25/13)   Shifting scales: comparing viral hepatits and HIV/AIDS mortality in the Global Burden of Disease Study 2010 - (11/20/13)   Virologic Response to Boceprevir Plus Peginterferon Alfa-2a (40KD) and Ribavirin in Treatment-naive Patients with Chronic Hepatitis C and HCV Genotype 1 Infection: Interim Analysis of Data From the International TriCo Study - (11/20/13)   Outcome of Treatment with Peginterferon alfa-2a (40KD) in HBeAg-positive and HBeAg-negative Patients with Chronic Hepatitis B (CHB) in the Real-World: Interim Analysis of Data from the Large European S-Collate Cohort - (11/20/13)   Morphometric Assessment of Quantitative Collagen and Liver Fibrosis in Patients With Chronic Hepatitis B Treated for Up to Five Years With Tenofovir Disoproxil Fumarate (TDF) - (11/19/13)   Seven Years of Treatment With Tenofovir Disoproxil Fumarate for Chronic Hepatitis B Virus Infection Is Safe and Well Tolerated and Associated With Sustained Virological, Biochemical, and Serological Responses With No Detectable Resistance - (11/19/13)   Long Term Nucleo(t)ide Treatment (entecavir, lamivudine) Reduces Mortality in Chronic Hepatitis B Patients - (11/19/13)   Gilead at AASLD: Sofosbuvir for GT 3, 2 and 1 - (11/18/13)   Twenty-Eight Day Safety and Efficacy of Tenofovir Alafenamide (TAF) Fumarate in Chronic Hepatitis B (CHB) Patients - (11/18/13)   Risk Prediction of Hepatocellular Carcinoma in Patients with Cirrhosis: The ADRESS-HCC Risk Model - (11/18/13)   HCV Treatment Reduces Liver Disease/Death/Transplant - (11/18/13)   Ending the Silent Epidemic of Viral Hepatitis in the U.S. - Ronald Valdiserri MD HHS - (11/18/13)   Sustained Virological Response After Protease Inhibitor-based Therapy For Hepatitis C Recurrence After Liver Transplantation: A Multicentric European Experience - (11/18/13)   Hepatitis C Screening & Prevalence among Veterans in Dept of Veterans Affairs Care in 2012 - (11/18/13)   Gilead at AASLD: Sofosbuvir for GT 3, 2 and 1 - (11/18/13)   BMS at AASLD - (11/18/13)   Boehringer Ingelheim - (11/18/13)   Merck at AASLD - (11/18/13)   Janssen at AASLD - (11/18/13)   Abbvie at AASLD - (11/18/13)   96 weeks of pegylated-interferon-alpha-2a plus tenofovir or placebo for the treatment of hepatitis delta: the HiDiT-2 study - (11/18/13)   Hepatitis B Virus Screening and Prevalence in US Veterans in Department of Veterans Affairs Care - (11/16/13)   Pharmacokinetics of MK-8742, an HCV NS5A Inhibitor, Following Single and Multiple Oral Doses of MK-8742 in Healthy Subjects - (11/14/13)   Screening in the Emergency Department Identifies a Large Cohort of Unrecognized Chronic HCV Infection Among Baby Boomers - (11/14/13)   Impact of Treatment on Long-Term Morbidity and Mortality in Chronic Hepatitis C Patients Receiving Care Through the U.S. Veterans Health Administration - (11/14/13)   Interferon-free Regimen Containing Setrobuvir in Combination with Ritonavir-boosted Danoprevir and Ribavirin with or without Mericitabine in HCV Genotype 1 Treatment-naive Patients: Interim Results from the ANNAPURNA Study - (11/14/13)   Safety, Tolerability, and Immunogenicity of GS-4774, an HBV-Specific Therapeutic Vaccine, in Healthy Volunteers - (11/14/13)   Lack of a Clinically Significant Pharmacokinetic Drug-Drug Interaction Between Sofosbuvir and GS-5816 in Healthy Volunteers - (11/14/13)   On-Treatment HCV RNA as a Predictor of Virologic Response in Sofosbuvir-Containing Regimens for Genotype 2/3 HCV Infection: Analysis of the FISSION, POSITRON, and FUSION Studies - (11/14/13)   Targeting lysyl oxidase like 2 (LOXL2) inhibits collagen cross-linking and accelerates reversal of pre-established liver fibrosis - (11/14/13)   Sofosbuvir Selects the NS5B S282T Mutation In Vitro in Genotype 1-6 Replicons and Is Not Cross-Resistant to Resistance-Associated Variants Selected by Other Classes of Antiviral Inhibitors - (11/14/13)   Population Pharmacokinetics of Sofosbuvir and Its Major Metabolite (GS-331007) in Healthy and HCV-Infected Adult Subjects - (11/14/13)   Nucleotide Analog Levels in Liver Explants From HCV Infected Subjects Undergoing Liver Transplantation After Up to 24 Weeks Sofosbuvir (GS-7977) With Ribavirin Treatment - (11/14/13)   HCV TARGET - Impact of Age on Safety and Treatment Response in Patients with Hepatitis - (11/14/13)   Responsible Use of New DAAs in 2014 and Beyond - written by David R Nelson MD Assistant Vice President for Research Professor of Medicine Director, Clinical and Translational Science Institute University of Florida Gainesville, USA - (11/14/13)   Virologic Response Rates to Sofosbuvir-Containing Regimens Are Similar in Patients With and Without Traditional Negative Predictive Factors: a Retrospective Analysis of Phase 3 Data - (11/13/13)   PRECLINICAL CHARACTERISTICS OF ACH-3422: A POTENT URIDINE NUCLEOTIDE PRODRUG FOR INHIBITION OF HEPATITIS C VIRUS NS5B RNA POLYMERASE - (11/13/13)   Selective inhibition of lysyl oxidase like 2 (LOXL2) using a therapeutic monoclonal antibody suppresses the progression of biliary fibrosis in novel PSC-like mouse model - (11/13/13)   Safety and Efficacy of BMS-791325, a Non-Nucleoside NS5B Polymerase Inhibitor, Combined With Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Patients Infected with Hepatitis C Virus Genotype 1 - (11/13/13)   Lack of Pharmacokinetic Interaction Between HCV Protease Inhibitor MK-5172 and HCV NS5A Inhibitor Daclatasvir in Healthy Volunteers - (11/13/13)   Virological Outcomes and Adherence to Treatment Algorithms in a Longitudinal Study of Patients with Chronic Hepatitis C Treated with Boceprevir or Telaprevir in the U.S. (HCV-TARGET) - (11/13/13)   STARTVerso4 PHASE III TRIAL OF FALDAPREVIR PLUS PEGYLATED INTERFERON α-2a AND RIBAVIRIN IN PATIENTS WITH HIV AND HCV GENOTYPE-1 CO-INFECTION - (11/11/13)   MASS BALANCE, METABOLIC PROFILE, AND THE ROLE OF HEPATIC AND BACTERIAL ENZYMES IN THE METABOLISM OF THE HCV POLYMERASE INHIBITOR, DELEOBUVIR - (11/11/13)   MASS BALANCE, METABOLIC PROFILE, AND THE ROLE OF HEPATIC AND BACTERIAL ENZYMES IN THE METABOLISM OF THE HCV POLYMERASE INHIBITOR, DELEOBUVIR - (11/11/13)   PHARMACOKINETIC INTERACTIONS OF FALDAPREVIR AND DELEOBUVIR AND THEIR INDIVIDUAL AND COMBINED EFFECT ON SELECTED CYTOCHROME P450 PROBE SUBSTRATES IN PATIENTS INFECTED WITH GENOTYPE-1 HCV - (11/11/13)   INTERFERON-FREE TREATMENT WITH FALDAPREVIR, DELEOBUVIR, AND RIBAVIRIN IN SOUND-C3: 95% SVR12 IN HCV GENOTYPE-1b - (11/11/13)   Sofosbuvir Plus Ribavirin in the Treatment of Chronic HCV Genotype 4 Infection in Patients of Egyptian Ancestry - (11/11/13)   Lack of a Clinically Important Pharmacokinetic Interaction Between Norgestimate/Ethinyl Estradiol and Sofosbuvir (SOF) or Ledipasvir (LDV) in HCV-Uninfected Female Subjects - (11/11/13)   Pharmacokinetics of Ledipasvir, an HCV-Specific NS5A Inhibitor, in HCV-Uninfected Subjects With Moderate or Severe Hepatic Impairment - (11/11/13)   Efficacy and Safety of Sofosbuvir in Patients According to Fibrosis Stage: An Analysis of Phase 3 Data - (11/11/13)   Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype 1 infection in treatment-naïve patients: efficacy in difficult-to-treat patient sub-populations in the QUEST-1 and 2 Phase III trials - (11/10/13)   Simeprevir (TMC435) with pegylated interferon-a-2a/ribavirin for treatment of chronic HCV genotype 1 infection in patients who relapsed after previous interferon-based therapy: efficacy and safety in patient sub-populations in the PROMISE Phase III trial - (11/10/13)   Resistance analyses of HCV isolates from patients treated with simeprevir in Phase IIB/III studies - (11/10/13)   A POOLED ANALYSIS OF TWO RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III TRIALS (STARTVerso1 AND 2) OF FALDAPREVIR PLUS PEGYLATED INTERFERON a-2a AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE-1 INFECTIONBACKGROUND - (11/10/13)   A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III TRIAL OF FALDAPREVIR IN COMBINATION WITH PEGYLATED INTERFERON α-2a AND RIBAVIRIN IN TREATMENT-EXPERIENCED PATIENTS WITH CHRONIC HCV GENOTYPE-1 INFECTION - (11/10/13)   SUBGROUP ANALYSES AND BASELINE PREDICTORS OF RESPONSE WITH FALDAPREVIR PLUS PEGYLATED INTERFERON a-2a AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE-1 INFECTION: A POOLED ANALYSIS OF STARTVerso1 AND 2 - (11/10/13)   EFFECT OF STEADY-STATE FALDAPREVIR ON THE PHARMACOKINETICS OF STEADY-STATE METHADONE AND BUPRENORPHINE/NALOXONE IN SUBJECTS ON STABLE ADDICTION MANAGEMENT THERAPY - (11/10/13)   EFFECT OF MULTIPLE ORAL DOSES OF FALDAPREVIR ON THE MULTIPLE DOSE PHARMACOKINETICS OF A COMBINATION ORAL TABLET OF ETHINYLESTRADIOL AND LEVONORGESTREL IN HEALTHY PREMENOPAUSAL FEMALE VOLUNTEERS - (11/10/13)   PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF FALDAPREVIR IN PATIENTS WITH DIFFERENT LEVELS OF RENAL IMPAIRMENT - (11/10/13)   Hepatitis Debrief by Mark Sulkowski MD - Professor of Medicine Division of Infectious Diseases and Gastroenterology/Hepatology Johns Hopkins University School of Medicine Baltimore, MD. - (11/08/13)   THE RISK FOR HCC AMONG PATIENTS WITH CHRONIC HCV INFECTION AND ADVANCED HEPATIC FIBROSIS FOLLOWING SVR - (11/08/13)   The global burden of liver disease attributable to hepatitis B, hepatitis C, and alcohol: increasing mortality, differing causes - (11/08/13)   Increases in HCV Hospital Liver-Related Admissions, Charges, Days-in-Hospital: aged 50-59 demonstrated the largest increases between 2002 and 2010 in the number of liver-related admissions (164%), liver-related hospital days (133%), and liver-related hospital charges (341%), Patients Aged 60+ Had 2nd Largest Increases.....ages 20-29 too - (11/07/13)   No Resistance Detected in Four Phase 3 Clinical Studies in HCV Genotypes 1-6 of Sofosbuvir + Ribavirin With or Without Peginterferon - (11/07/13)   HCV RNA "Target Detected" After "Target Not Detected" During IFN-free Treatment: Time to Worry or Not? - (11/07/13)   All-Oral Therapy With Sofosbuvir Plus Ribavirin For the Treatment of HCV Genotype 1, 2, and 3 Infection in Patients Co-infected With HIV (PHOTON-1) - (11/06/13)   All-Oral Combination of Daclatasvir Plus Asunaprevir in Interferon-Ineligible Naïve/Intolerant and Nonresponder Japanese Patients Chronically Infected With HCV Genotype 1b: Results From a Phase 3 Trial - (11/06/13)   Sofosbuvir and Ledipasvir Fixed-Dose Combination with and without Ribavirin in Treatment-Naïve and Previously Treated Patients with Genotype 1 Hepatitis C: The LONESTAR Study - (11/06/13)   Pretransplant Sofosbuvir and Ribavirin to Prevent Recurrence of HCV Infection After Liver Transplantation - (11/06/13)   Combination Oral, Ribavirin Free, Antiviral Therapy to Optimize Treatment Outcomes for Hepatitis C Treatment Naïve Patients: Interim Results from the NIAID SYNERGY Trial (6 & 12 weeks therapy) - (11/06/13)   Initial Evaluation of the Sofosbuvir Compassionate Use Program for Patients With Severe Recurrent HCV Following Liver Transplantation - (11/06/13)   Safety of Ribavirin-containing Regimens of ABT-450/r, ABT-333, and ABT-267 for the Treatment of HCV Genotype 1 Infection and Efficacy in Subjects With Ribavirin Dose Reductions - (11/06/13)   High Medication Adherence in HCV-Infected Patients Taking a Triple-DAA Regimen for 12 Weeks - (11/06/13)   Low Relapse Rate Leads to High Concordance of SVR4 and SVR12 With SVR24 After Treatment With ABT-450/r, ABT-267, ABT-333 + Ribavirin in Patients With Chronic HCV Genotype 1 Infection in the AVIATOR Study - (11/06/13)   Phase 2b Study of the Interferon-Free and Ribavirin-Free Combination of Daclatasvir, Asunaprevir, and BMS-791325 for 12 Weeks in Treatment-Naive Patients With Chronic HCV Genotype 1 Infection - (11/05/13)   SVR results of a once-daily regimen of simeprevir (SMV, TMC435) plus sofosbuvir (SOF, GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-naïve and prior null responder patients: The COSMOS study - (11/05/13)   Sofosbuvir in Combination With PegIFN and Ribavirin for 12 Weeks Provides High SVR Rates in HCV-Infected Genotype 2 or 3 Treatment- Experienced Patients with and without Compensated Cirrhosis: Results from the LONESTAR-2 Study - (11/05/13)   Sofosbuvir and Ribavirin for the Treatment of Established Recurrent Hepatitis C Infection After Liver Transplantation: Preliminary Results of a Prospective, Multicenter Study - (11/05/13)   INCIVO® (TELAPREVIR) DATA TO BE PRESENTED AT AASLD AND ISPOR, TWO MAJOR INTERNATIONAL CONGRESSES, ON THE ANTI-VIRAL RESPONSE, SAFETY, TOLERABILITY AND COST-EFFECTIVENESS OF AN INCIVO® (TELAPREVIR) BASED REGIMEN IN THE TREATMENT OF GENOTYPE-1 CHRONIC HEPATITIS C - (11/05/13)   MK-8742, an HCV NS5A Inhibitor With a Broad Spectrum of HCV Genotypic Activity, Demonstrates Potent Antiviral Activity in Genotype-1 and -3 HCV-Infected Patients - (11/05/13)   Deep Sequencing of HCV NS5A From a 3-Day Study of GS-5816 Monotherapy Confirms the Potency of GS-5816 Against Pre-Existing Genotype 1-3 NS5A Resistance-Associated Variants - (11/05/13)   PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF FALDAPREVIR IN PATIENTS WITH DIFFERENT LEVELS OF RENAL IMPAIRMENT - (11/05/13)   Resistance Analysis [and activity] of Genotype-1 and -3 HCV-Infected Patients Receiving MK-8742, an HCV NS5A Inhibitor With Potent Antiviral Activity, in a Ph1b Monotherapy Study - (11/05/13)   High Efficacy and Safety of the All-Oral Combination Regimen, MK-5172 / MK-8742 ± RBV for 12 Weeks in HCV Genotype 1 Infected Patients: The C-WORTHY Study - (11/05/13)   Sofosbuvir + Ribavirin for 12 or 24 Weeks for Patients With HCV Genotype 2 or 3: the VALENCE Trial - (11/04/13)   VX-135, A Once-daily Nucleotide HCV Polymerase Inhibitor, Was Well Tolerated And Demonstrated Potent Antiviral Activity When Given With Ribavirin In Treatment-naïve Patients With Genotype 1 HCV - (11/04/13)   GS-5816, a Once-Daily NS5A Inhibitor, Demonstrates Potent Antiviral Activity in Patients With Genotype 1-4 HCV Infection in a 3 Day Monotherapy Study - (11/04/13)   Once Daily Sofosbuvir/Ledipasvir Fixed-Dose Combination With or Without Ribavirin: Data From the ELECTRON Trials - (11/04/13)   Interferon- and Ribavirin-free Regimen of ABT-450/r + ABT-267 in HCV Genotype 1b-infected Treatment-naïve Patients and Prior Null Responders - (11/04/13)   Efficacy and Safety of an Interferon-Free Regimen of MK-5172 + Ribavirin for 12 Weeks or 24 Weeks in Treatment-Naive, Noncirrhotic Subjects With HCV GT1 Infection: The C-SPIRIT Study - (11/04/13)   Rapid and Consistent Virologic Responses in a Phase 2 Trial of a New All-Oral Combination of Faldaprevir, Deleobuvir and PPI-668, with and without Ribavirin, in Patients with HCV Genotype-1a Infection - (11/04/13)   BMS Submits First All-Oral, Interferon-Free and Ribavirin-Free Treatment Regimen for Regulatory Review in Japan for Patients with Chronic Hepatitis C Infection - (11/02/13)   Simeprevir Administered Once Daily as Part of Combination Therapy Demonstrates Sustained Virologic Response in Treatment-Naïve and Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients - (11/02/13)   Gilead Announces Phase 2 Results for Sofosbuvir-Based Regimens in Hepatitis C Patients Before and After Liver Transplantation - (11/02/13)   Gilead Announces Phase 2 Results for Sofosbuvir-Based Regimens in Hepatitis C Patients Before and After Liver Transplantation - (11/02/13)   GILEAD ANNOUNCES PHASE 3 RESULTS FOR AN ALL-ORAL, SOFOSBUVIR-BASED REGIMEN FOR THE TREATMENT OF HEPATITIS C IN PATIENTS CO-INFECTED WITH HIV - (11/02/13)   Presidio Pharmaceuticals Announces a High Rate of Virologic Response in an Ongoing Phase 2 Hepatitis C Trial of a New All-Oral Combination of Presidio's PPI-668 With Boehringer Ingelheim's Faldaprevir - (11/02/13)   Boehringer Ingelheim's interferon-free hepatitis C treatment portfolio strengthened by promising Phase II data - (11/02/13)   Phase III data show Boehringer Ingelheim's faldaprevir* was highly effective in a broad range of patients with genotype-1 hepatitis C - (11/02/13)